These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28993963)

  • 21. Protective effects of dietary supplementation with natural ω-3 polyunsaturated fatty acids on the visual acuity of school-age children with lower IQ or attention-deficit hyperactivity disorder.
    Wu Q; Zhou T; Ma L; Yuan D; Peng Y
    Nutrition; 2015; 31(7-8):935-40. PubMed ID: 26015389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical and Psychological Effects of Omega-3/6 Supplements in Male Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Clinical Trial.
    Matsudaira T; Gow RV; Kelly J; Murphy C; Potts L; Sumich A; Ghebremeskel K; Crawford MA; Taylor E
    J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):775-82. PubMed ID: 26682998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of vitamin D supplementation as adjunctive therapy to methylphenidate on ADHD symptoms: A randomized, double blind, placebo-controlled trial.
    Mohammadpour N; Jazayeri S; Tehrani-Doost M; Djalali M; Hosseini M; Effatpanah M; Davari-Ashtiani R; Karami E
    Nutr Neurosci; 2018 Apr; 21(3):202-209. PubMed ID: 27924679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis.
    Bloch MH; Qawasmi A
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):991-1000. PubMed ID: 21961774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of phosphatidylserine containing omega3 fatty acids in ADHD children: a double-blind placebo-controlled trial followed by an open-label extension.
    Manor I; Magen A; Keidar D; Rosen S; Tasker H; Cohen T; Richter Y; Zaaroor-Regev D; Manor Y; Weizman A
    Eur Psychiatry; 2013 Aug; 28(6):386-91. PubMed ID: 23312676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Omega-3 and Korean Red Ginseng in Children with Subthreshold ADHD: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Lee J; Lee SI
    J Atten Disord; 2021 Dec; 25(14):1977-1987. PubMed ID: 32847461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder.
    Hariri M; Djazayery A; Djalali M; Saedisomeolia A; Rahimi A; Abdolahian E
    Malays J Nutr; 2012 Dec; 18(3):329-35. PubMed ID: 24568073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Supplementation with high-content docosahexaenoic acid triglyceride in attention-deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.
    Rodríguez C; García T; Areces D; Fernández E; García-Noriega M; Domingo JC
    Neuropsychiatr Dis Treat; 2019; 15():1193-1209. PubMed ID: 31190827
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omega 3/6 fatty acids for reading in children: a randomized, double-blind, placebo-controlled trial in 9-year-old mainstream schoolchildren in Sweden.
    Johnson M; Fransson G; Östlund S; Areskoug B; Gillberg C
    J Child Psychol Psychiatry; 2017 Jan; 58(1):83-93. PubMed ID: 27545509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
    Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
    J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: a case-control study.
    Colter AL; Cutler C; Meckling KA
    Nutr J; 2008 Feb; 7():8. PubMed ID: 18275609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omega-3 Polyunsaturated Fatty Acids for Core Symptoms of Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Liu TH; Wu JY; Huang PY; Lai CC; Chang JP; Lin CH; Su KP
    J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37656283
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.